MDL Mass Tort & Class Action Monitor
Developed to serve primarily as a litigation scouting report for plaintiff and defense counsel, insurers and legal service providers, HarrisMartin’s MDL Mass Tort & Class Action Monitor covers significant new filings and decisions in the JPML, MDL and related mass tort arenas. The quick delivery of breaking news and additional features will keep you within close range of every development occurring in the high-stakes environment of mass torts litigation — where minutes can make a difference. The MDL Mass Tort & Class Action Monitor is an online-only offering that includes frequent email updates and is available at no charge to annual and event sponsors of HarrisMartin’s CLE Conferences.
SEARCH THE ARCHIVES
The plaintiff in the first Taxotere permanent hair loss case to go before a jury has asked a Louisiana federal judge for a new trial, arguing that the defense verdict was erroneously based upon the unreliable testimony of defendants’ corporate expert.
A Florida federal judge has refused to dismiss a consolidated class action complaint accusing the makers of Monat hair care products of misrepresenting their safety and efficacy, ruling that the plaintiffs sufficiently alleged design and manufacturing defects, and causation.
A Georgia woman has been awarded $33.7 million in the first bellwether trial in the Philadelphia inferior vena cava filter mass tort litigation, with the jury finding that Rex Medical and Argon Medical Devices defectively designed the device.
A Massachusetts federal judge has denied GlaxoSmithKline’s motion for summary judgment in 50 cases on the Zofran multidistrict litigation docket, finding the plaintiffs presented sufficient evidence that the drug can cause orofacial abnormalities other than cleft palate.
The judge overseeing the federal Zofran birth defect multidistrict litigation docket has excluded as untimely portions of a supplemental report by one of plaintiffs’ causation experts, explaining that it does not address new scientific studies or new data, or correct an error.
Issue #32, October 2019
The U.S. Judicial Panel on Multidistrict Litigation will hear the petition to create a MDL docket for claims relating to Allergan’s Biocell textured breast implants at its December 4 hearing in Austin, according to a recent hearing session order.
The Food and Drug Administration has recommended a boxed warning for saline and silicone gel-filled breast implants, which would caution doctors and patients of the risk of breast implant-associated anaplastic large cell lymphoma.
In a new lawsuit, a Colorado man contends his long-term ingestion of Zantac (ranitidine) caused him to develop bladder cancer because the antacid drug contains “staggering amounts” of N-nitrosodimethylamine (NDMA), a probable carcinogen.
Attorneys general from four states have announced that they reached a $48 billion settlement framework with Cardinal Health, McKesson Corp., AmerisourceBergen Corp., Johnson & Johnson and Teva Pharmaceuticals over their alleged role in the opioid epidemic.
Drug maker Sanofi has announced that it is voluntarily recalling its over-the-counter heartburn drug Zantac (ranitidine) amid concerns that it was contaminated by a probable human carcinogen known as N-nitrosodimethylamine (NDMA).